GALT
Galectin Therapeutics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+23/100
Last price
3.82
▲ 0.06 (1.46%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.74
Prev close
3.76
Day high
3.84
Day low
3.73
Volume
32.44K
Market cap
$384.74M
P/E (TTM)
—
52W range
2.03 – 7.13
Day trading desk
Gap from prior close
-0.53%
Prior close 3.76
VWAP
3.79
+0.60% from price
Relative volume
0.07×
Quiet session
Session range
2.79%
3.73 – 3.84
Position in range
81%
Near session high
ATR (14D)
0.21
5.46% of price
Prior day high
3.79
PDH
Prior day low
3.57
PDL
Bid / ask spread
—
Quote not published
Session volume
28.16K
Avg 387.94K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.68%
-3.2%
1M
-7.85%
-9.0%
3M
-12.70%
-15.7%
6M
+71.85%
+57.3%
YTD
-8.29%
-21.9%
1Y
-14.08%
-29.4%
3Y
+98.70%
+17.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GALT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+34.38M
Net buying
Buy transactions
6
34.48M shares
Sell transactions
5
106.41K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
53.53M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | UIHLEIN RICHARD E Director and Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 34.38M | $105.81M | Indirect |
| Jul 14, 26 | JAMIL KHURRAM Officer |
CONVERSION | 16.25K | $49.40K | Direct |
| Jul 14, 26 | JAMIL KHURRAM Officer |
SELL | 16.25K | $83.28K | Direct |
| Jun 29, 26 | SHLEVIN HAROLD H Director |
CONVERSION | 30.00K | $36.90K | Direct |
| Jun 29, 26 | JAMIL KHURRAM Officer |
CONVERSION | 52.04K | $129.48K | Direct |
| Jun 29, 26 | SHLEVIN HAROLD H Director |
SELL | 30.00K | $150.89K | Direct |
| Jun 29, 26 | JAMIL KHURRAM Officer |
SELL | 52.04K | $262.08K | Direct |
| Jun 23, 26 | JAMIL KHURRAM Officer |
CONVERSION | 7.56K | $9.29K | Direct |
| Jun 23, 26 | JAMIL KHURRAM Officer |
SELL | 7.56K | $23.73K | Direct |
| May 26, 26 | JAMIL KHURRAM Officer |
CONVERSION | 568 | $699 | Direct |
| May 26, 26 | JAMIL KHURRAM Officer |
SELL | 568 | $1.76K | Direct |
| Feb 6, 26 | ELDRED KARY N. Director |
BUY | 300 | $810 | Direct |
| Jan 16, 26 | UIHLEIN RICHARD E Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 13.16K | $40.00K | Direct |
| Jan 6, 26 | LEWIS JOEL Chief Executive Officer |
SELL | 84.00K | $321.13K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
10X FUND, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
CALLICUTT JACK W |
Chief Financial Officer | 7.61K | Sale |
CZIRR JAMES C |
Beneficial Owner of more than 10% of a Class of Security | 1.05M | Conversion of Exercise of derivative security |
ELDRED KARY N. |
Director | 70.11K | Purchase |
FREEMAN KEVIN D |
Director | 137.27K | Purchase |
JAMIL KHURRAM |
Officer | 0 | Conversion of Exercise of derivative security |
LEWIS JOEL |
Chief Executive Officer | 834.59K | Sale |
SHLEVIN HAROLD H |
Director | 6.50K | Conversion of Exercise of derivative security |
UIHLEIN RICHARD E |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
ZORDANI RICHARD A. JR |
Director | 44.08K | Purchase |
Fundamentals
Market cap$384.74M
Enterprise value$512.08M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-28.03M
EPS (TTM)$-0.43
Free cash flow$-14.86M
Total cash$13.27M
Total debt$143.96M
Book value / share$-2.10
Shares outstanding100.85M
Float47.77M
Short % of float12.13%
Dividend yield0.00%
Beta (5Y)0.38
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.27
PEG ratio-36.15
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-64.18%
Debt / equity—
Current ratio0.10
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $14.29M | $36.57M | $32.13M | $31.74M | -60.9% |
| Selling, general & admin | $5.79M | $5.86M | $5.94M | $6.62M | -1.1% |
| Total operating expense | $20.09M | $42.43M | $38.07M | $38.35M | -52.7% |
| Operating income | -$20.09M | -$42.43M | -$38.07M | -$38.35M | +52.7% |
| Net interest income | -$7.20M | -$5.20M | -$2.56M | -$981.00K | -38.5% |
| Pre-tax income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | +34.5% |
| Net income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | +34.5% |
| Net income to common | -$30.97M | -$47.20M | -$44.80M | -$38.87M | +34.4% |
| Basic EPS | -0.48 | -0.76 | -0.74 | -0.65 | +36.8% |
| Diluted EPS | -0.48 | -0.76 | -0.74 | -0.65 | +36.8% |
| EBIT | -$23.51M | -$41.51M | -$38.27M | -$37.74M | +43.4% |
| EBITDA | -$23.45M | -$41.47M | -$38.24M | -$37.71M | +43.4% |
| Basic shares | 63.90M | 62.31M | 60.16M | 59.39M | +2.6% |
| Diluted shares | 63.90M | 62.31M | 60.16M | 59.39M | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $17.72M | $15.12M | $25.66M | $18.59M | +17.2% |
| Cash & short-term investments | $17.72M | $15.12M | $25.66M | $18.59M | +17.2% |
| Total current assets | $19.44M | $17.25M | $27.71M | $20.55M | +12.7% |
| Property, plant & equipment | $0 | $0 | $0 | $0 | — |
| Total assets | $19.53M | $17.50M | $28.20M | $21.29M | +11.6% |
| Total current liabilities | $8.03M | $35.41M | $15.68M | $13.01M | -77.3% |
| Current debt | — | $21.12M | — | — | — |
| Long-term debt | $133.74M | $85.11M | $71.74M | $39.83M | +57.1% |
| Total debt | $133.76M | $106.25M | $71.79M | $39.87M | +25.9% |
| Total liabilities | $145.73M | $120.56M | $88.44M | $53.48M | +20.9% |
| Retained earnings | -$432.55M | -$401.57M | -$354.37M | -$309.57M | -7.7% |
| Shareholder equity | -$126.19M | -$103.07M | -$60.24M | -$32.19M | -22.4% |
| Working capital | $11.41M | -$18.16M | $12.03M | $7.54M | +162.8% |
| Net tangible assets | -$126.19M | -$103.07M | -$60.24M | -$32.19M | -22.4% |
| Shares issued | 65.20M | 63.16M | 61.85M | 59.43M | +3.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | +34.5% |
| Depreciation & amortisation | $53.00K | $37.00K | $33.00K | $32.00K | +43.2% |
| Stock-based compensation | $1.66M | $2.45M | $2.26M | $2.87M | -32.2% |
| Change in working capital | $609.00K | $2.28M | $4.68M | $4.97M | -73.3% |
| Operating cash flow | -$23.88M | -$41.77M | -$32.97M | -$31.06M | +42.8% |
| Investing cash flow | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $26.48M | $31.23M | $40.03M | $10.00M | -15.2% |
| Free cash flow | -$23.88M | -$41.77M | -$32.97M | -$31.06M | +42.8% |
| End cash position | $17.72M | $15.12M | $25.66M | $18.59M | +17.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $2.13M | $2.23M | $1.93M | $2.61M | $3.26M | — | -4.3% |
| Selling, general & admin | $1.85M | $1.85M | $1.43M | $1.59M | $1.36M | — | +0.1% |
| Total operating expense | $3.98M | $4.08M | $3.37M | $4.20M | $4.63M | — | -2.3% |
| Operating income | -$3.98M | -$4.08M | -$3.37M | -$4.20M | -$4.63M | — | +2.3% |
| Net interest income | -$1.98M | -$1.95M | -$1.91M | -$1.78M | -$1.80M | — | -1.2% |
| Pre-tax income | -$9.11M | -$5.05M | -$5.50M | -$8.18M | -$7.52M | — | -80.6% |
| Net income | -$9.11M | -$5.05M | -$5.50M | -$8.18M | -$7.52M | — | -80.6% |
| Net income to common | -$9.18M | -$5.07M | -$5.56M | -$8.22M | -$7.58M | — | -81.1% |
| Basic EPS | -0.14 | -0.08 | — | -0.13 | -0.12 | -0.15 | -75.0% |
| Diluted EPS | -0.14 | -0.08 | — | -0.13 | -0.12 | -0.15 | -75.0% |
| EBIT | -$7.11M | -$3.06M | -$3.56M | -$6.36M | -$5.70M | — | -132.5% |
| EBITDA | -$7.11M | -$3.05M | -$3.52M | -$6.36M | -$5.69M | — | -133.3% |
| Basic shares | 65.88M | 65.78M | — | 64.20M | 63.45M | 63.20M | +0.1% |
| Diluted shares | 65.88M | 65.78M | — | 64.20M | 63.45M | 63.20M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $13.27M | $14.11M | $17.72M | $11.53M | $13.77M | — | -6.0% |
| Cash & short-term investments | $13.27M | $14.11M | $17.72M | $11.53M | $13.77M | — | -6.0% |
| Total current assets | $14.66M | $15.69M | $19.44M | $12.73M | $15.43M | — | -6.6% |
| Property, plant & equipment | — | — | $0 | — | — | — | — |
| Total assets | $14.83M | $15.76M | $19.53M | $12.87M | $15.60M | — | -5.9% |
| Total current liabilities | $151.62M | $7.31M | $8.03M | $136.44M | $10.77M | — | +1,975.0% |
| Current debt | $137.70M | — | — | $122.28M | — | $97.11M | — |
| Long-term debt | — | $135.71M | $133.74M | — | $120.46M | $10.81M | — |
| Total debt | $137.76M | $135.72M | $133.76M | $122.31M | $120.51M | — | +1.5% |
| Total liabilities | $151.68M | $146.00M | $145.73M | $138.17M | $132.77M | — | +3.9% |
| Retained earnings | -$446.79M | -$437.61M | -$432.55M | -$426.98M | -$418.76M | — | -2.1% |
| Shareholder equity | -$136.85M | -$130.24M | -$126.19M | -$125.30M | -$117.17M | — | -5.1% |
| Working capital | -$136.96M | $8.38M | $11.41M | -$123.72M | $4.65M | — | -1,733.6% |
| Net tangible assets | -$136.85M | -$130.24M | -$126.19M | -$125.30M | -$117.17M | — | -5.1% |
| Shares issued | 66.31M | 65.86M | 65.20M | 64.47M | 64.06M | — | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$9.11M | -$5.05M | -$5.50M | -$8.18M | -$7.52M | -80.6% |
| Depreciation & amortisation | $4.00K | $12.00K | $41.00K | $0 | $2.00K | -66.7% |
| Stock-based compensation | $963.00K | $686.00K | $195.00K | $496.00K | $500.00K | +40.4% |
| Change in working capital | $2.39M | $1.31M | -$1.18M | $1.73M | -$1.03M | +82.8% |
| Operating cash flow | -$2.44M | -$3.87M | -$6.04M | -$3.54M | -$6.60M | +36.9% |
| Financing cash flow | $1.60M | $257.00K | $12.24M | $1.30M | $12.94M | +521.4% |
| Free cash flow | -$2.44M | -$3.87M | -$6.04M | -$3.54M | -$6.60M | +36.9% |
| End cash position | $13.27M | $14.11M | $17.72M | $11.53M | $13.77M | -6.0% |
Options analytics
Put / call volume
1.30
Put-heavy session
Put / call open interest
0.59
Positioning, not flow
Max pain
5.00
+31.1% from spot
ATM implied vol
132.8%
Nearest strike to spot
Skew (10% OTM)
+35.9%
Puts bid over calls
Call volume
10
Contracts, this expiry
Put volume
13
Contracts, this expiry
Heaviest call OI
5.00
2.58K contracts
Heaviest put OI
2.50
1.27K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.09 | -0.14 | -55.6% |
| Mar 2026 | -0.06 | -0.08 | -33.3% |
| Dec 2025 | -0.10 | -0.08 | +20.0% |
| Sep 2025 | -0.11 | -0.13 | -18.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.05 | 1 | $0 | 0.0% |
| Next quarter | -0.05 | 1 | $0 | 0.0% |
| Current year | -0.30 | 1 | $0 | 0.0% |
| Next year | -0.23 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$11.00
High target$11.00
Low target$11.00
Implied upside188.34%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders53.08%
Held by institutions15.66%
Institutions holding131
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.85
-1.02% from price
SMA 20
3.87
-1.36% from price
SMA 50
3.74
+1.97% from price
SMA 100
3.55
+7.59% from price
SMA 200
3.23
+18.24% from price
EMA 12
3.85
-0.97% from price
EMA 26
3.87
-1.45% from price
EMA 50
3.80
+0.37% from price
RSI (14)
48.0
Neutral
MACD (12,26,9)
-0.02
Hist -0.03
ATR (14)
0.21
5.46% of price
Realised vol 30D
58.2%
Annualised
Bollinger upper
4.10
20, 2σ
Bollinger lower
3.64
20, 2σ
50 / 200 cross
Golden
3.74 vs 3.23
Trend bias
Above 200
+18.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.75
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
58.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-68.0%
Peak to trough
Max drawdown 5Y
-80.0%
Peak to trough
ATR 14
0.21
5.46% of price
Beta (reported)
0.38
5Y monthly, from filing
Short interest
Shares short
9.34M
Prior 9.00M
Change vs prior
+3.7%
Shorts adding
% of float
12.13%
Elevated
% of shares out
9.26%
Against total outstanding
Days to cover
29.1
Crowded exit
Float
47.77M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 17, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 2, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Dec 27, 24 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Nov 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 16, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 9, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 1, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 17, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 3, 23 | HC Wainwright & Co. | MAINTAINED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:6
Split dateMar 23, 2012
SEC filings
Proxy Statements
PRE 14A · 2026-10-02
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-23
Periodic Financial Reports
10-Q · 2026-05-15
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-04-08
Corporate Changes & Voting Matters
8-K · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-03-17
Headlines
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
GlobeNewswire · 1d ago
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 27d ago
Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
PR Newswire · 44d ago
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
GlobeNewswire · 54d ago
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
GlobeNewswire · 64d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.